Indian Pharmaceutical Contract Manufacturing Market Report 2022: Low Manufacturing Cost, Easy Availability of Skilled Workers, and Well-Established Certified Plants Driving Growth – ResearchAndMarkets.com

Indian Pharmaceutical Contract Manufacturing Market Report 2022: Low Manufacturing Cost, Easy Availability of Skilled Workers, and Well-Established Certified Plants Driving Growth – ResearchAndMarkets.com




Indian Pharmaceutical Contract Manufacturing Market Report 2022: Low Manufacturing Cost, Easy Availability of Skilled Workers, and Well-Established Certified Plants Driving Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Indian Pharmaceutical Contract Manufacturing Market Research and Forecast 2022-2028” report has been added to ResearchAndMarkets.com’s offering.

The Indian pharmaceutical contract manufacturing market is anticipated to grow at a favourable CAGR of around 13.3% during the forecast period. Being one of the free trade agreement members, India holds the access to the best established and emerging pharmaceutical markets in the Asia-Pacific region.

Due to the favorable factors, such as low manufacturing cost, easy availability of skilled workers, and well-established certified plants, the Indian pharmaceutical contract manufacturing has witnessed higher growth in the forthcoming year. According to the FDA. Maharashtra.Gov, in India nearly 58 companies have certification including Emcure Pharmaceuticals Ltd. is certified with US FDA/WHO/Medical control council(MCC), and UK MHRA, and Cipla Ltd., is been certified with US FDA/ MHRA/ Therapeutic Control Council, and ANVISA(Brazil).

In basic manufacturing of medical drugs and devices, India has a superior edge over nations, such as Vietnam, China, and Ireland, owing to the availability of immense raw material, technical workforce, and WHO-approved production premises. During the COVID-19 pandemic, several initiatives were taken by the Union Cabinet to boost the Indian pharmaceutical industry, which includes the amendment of the existing foreign direct investment (FDI), which allows the foreign investors to invest up to 100% under the automatic route for manufacturing medical devices. With the advent of global pharmaceutical organizations, and their vast presence in India, the concept of contract manufacturing has steadily evolved, which in turn boosts the growth of India’s pharmaceutical contract manufacturing market.

Market Segmentation

  1. Indian Pharmaceutical Contract Manufacturing Market Research and Analysis by Category
  2. Indian Pharmaceutical Contract Manufacturing Market Research and Analysis by Type
  3. Indian Pharmaceutical Contract Manufacturing Market Research and Analysis by Product
  4. Indian Pharmaceutical Contract Manufacturing Market Research and Analysis by Services

The Report Covers

  • Comprehensive research methodology of the Indian pharmaceutical contract manufacturing market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Indian pharmaceutical contract manufacturing market.
  • Insights about market determinants that are stimulating the Indian pharmaceutical contract manufacturing market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Key Topics Covered:

1. Report Summary

2. Market Overview and Insights

3. Competitive Landscape

4. Market Segmentation

5. Company Profiles

Companies Mentioned

  • Agrata Biotech Ltd.
  • Ankur Drugs and Pharma Ltd.
  • Aurobindo Pharma
  • BDR Pharmaceuticals Internationals Pvt. Ltd.
  • Ceegolabs Pvt Ltd.
  • Ciron Drugs & Pharmaceuticals Pvt. Ltd.
  • Contract Pharmaceuticals Ltd.
  • Cosway Biosciences
  • Cubic Lifesciences Pvt Ltd.
  • Daffohils Laboratories Pvt Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/ewmosq

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900